In the past few years, evidence has emerged for newer interventions; sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i), non‐steroidal selective mineralocorticoid receptor antagonist (nsMRA) finerenone, and glucagon‐like peptide 1 receptor agonist (GLP1 RA) that can further reduce the risk of ESKD and CVD (including heart failure) in people with CKD.8, 9, 10. This evidence concerns the gene NR3C2 and heart failure.